Details of the Drug

General Information of Drug (ID: DMWK679)

Drug Name
OMP-18R5
Synonyms Vantictumab; Wnt inhibitors (mAb, cancer), OncoMed Pharmaceuticals
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
UNII
88WBI2D80S
DrugBank ID
DB12956
TTD ID
D00GPY

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Frizzled-7 receptor (FZD7) TTUQMO5 FZD7_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01345201) A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors. U.S. National Institutes of Health.
2 Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11717-22.